Recent Pfizer Press Releases

  • 3/18/08 5:00 pm EDT

    Gene Marker Technology to Support Global Livestock Producers

    NEW YORK--(BUSINESS WIRE)--Pfizer Animal Health today announced it will acquire two market-leading livestock genomics companies: Catapult Genetics, Pty., Ltd., focused on developing and commercializing innovative livestock DNA tests and gene markers to assist global food producers, processors and retailers in improving profitability and quality in the global food chain; and Bovigen, LLC, which markets DNAmore...
  • 3/12/08 11:43 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Martin Mackay, President, Pfizer Global Research & Development, at the Lehman Brothers Global Healthcare Conference on Wednesday, March 19th at 10:45 a.m. Eastern Daylight Savings Time. To view and listen to the webcast, visit our web site homepage at www.pfizer.com and click on the “Lehman Brothersmore...
  • 3/11/08 4:16 pm EDT

    Remains Outside Counsel Through Transition Period

    NEW YORK--(BUSINESS WIRE)--Pfizer said today that Senior Vice President and General Counsel Allen Waxman is leaving the company for personal reasons. Mr. Waxman will remain outside counsel to Pfizer through a transition period. Pfizer said David Reid, currently Senior Vice President and Managing Director, will assume Mr. Waxman’s responsibilities on an interim basis while the company conducts a search for a permanent successormore...
  • 3/10/08 2:17 pm EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Pfizer Inc. Chief Medical Officer, Joseph Feczko, at the Cowen and Company 28th Annual Healthcare Conference on Monday, March 17th at 11:30 a.m. Eastern Daylight Savings Time. To view and listen to the webcast, visit our web site homepage at www.pfizer.com and click on the “Cowen and Company 28thmore...
  • 3/7/08 1:34 pm EST
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that the Court of Appeals for the Federal Circuit has upheld the two main U.S. patents covering Celebrex, the company’s selective non-steroidal anti-inflammatory (NSAID) medicine used to treat pain and inflammation. The patents had been challenged by generic manufacturer Teva Pharmaceuticals USA. The panel ruled that the patents (Nos. 5,466,823 and 5,563,165) covering themore...
  • 3/5/08 8:00 am EST
    • Accelerating Pipeline with Sharpened Focus on Key Disease Areas; Phase III Pipeline Expected to Grow to 24-28 Programs By End of 2009, Up from 16 Today
    • Seizing Opportunities for Global Growth by Optimizing Patent Protected Portfolio, and Expanding in Emerging and Established Markets through Innovative Commercial Models
    • Reaffirming 2008 Guidance; Continuing to Create a Lower, More Flexible Cost Base
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc today reviewed strategies to accelerate and refocus Pfizer’s pipeline and capture new opportunities for global growth at a meeting for investment analysts. “We have made real changes in how we operate our business – in our structure, culture and leadership – so that we have a much stronger foundation in place for pursuing the many opportunities before us,” said Chairmanmore...
  • 3/4/08 4:56 pm EST
    NEW YORK & HOUSTON--(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) today announced the commencement of the tender offer by its wholly-owned subsidiary, Explorer Acquisition Corp., for all outstanding shares of common stock of Encysive Pharmaceuticals Inc. (NASDAQ:ENCY) for $2.35 per share, net to the seller in cash. The tender offer is being made pursuant to an Offer to Purchase, dated March 4, 2008, and in connection with the Agreement and Plan of Merger, datedmore...
  • 3/3/08 10:10 am EST
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc today named William Ringo as the company’s new Senior Vice President of Strategy and Business Development with responsibility for guiding Pfizer’s overall strategic planning and business development activities, reporting to Chairman and Chief Executive Officer Jeff Kindler. He will join Pfizer’s Executive Leadership Team. Mr. Ringo is a senior corporate bio-pharmaceutical executive withmore...
  • 3/3/08 8:00 am EST

    Latest step in Pfizers Strategy to Broaden Scope of Research in Key Therapeutic Areas

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc today announced that it has entered into an agreement to acquire Serenex, Inc., a privately-held biotechnology company with a Phase I clinical candidate and an extensive compound library that targets Heat Shock Protein 90 (Hsp90), an exciting target in the fight against cancer. As per the agreement, Pfizer will acquire the rights to SNX-5422, an oral Hsp90 inhibitor currently in Phase I trials for themore...
  • 2/28/08 10:11 am EST
    NEW YORK--(BUSINESS WIRE)-- Pfizer Inc said today that it will seek to appeal a ruling of the Court of Appeal of The Hague in the Netherlands that Pfizer’s atorvastatin enantiomer patent is invalid. The patent (EP 409,281) had been challenged by generics manufacturer Ranbaxy and expires in July 2010. The decision has no commercial impact because Pfizer’s basic patent covering Lipitor (EP 247,633) remains in force and expiresmore...